<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38969540</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>23</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Estimation of the poliovirus type 2 immunity gap in South Africa.</ArticleTitle><Pagination><StartPage>126062</StartPage><MedlinePgn>126062</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.06.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)00703-5</ELocationID><Abstract><AbstractText>In the context of polio eradication efforts, accurate assessment of vaccination programme effectiveness is essential to public health planning and decision making. Such assessments are often based on zero-dose children, estimated using the number of children who did not receive the first dose of the Diphtheria-Tetanus-Pertussis containing vaccine as a proxy. Our study introduces a novel approach to directly estimate the number of children susceptible to poliovirus type 2 (PV2) and uses this approach to provide district-level estimates for South Africa of susceptible children born between 2017 and 2022. We used district-level data on annual doses of inactivated poliovirus vaccine (IPV) administered, live births, and population sizes, from 2017 through 2022. We imputed missing vaccination data, implemented flexible assumptions regarding dose distribution in the eligible population, and used estimated efficacy values for one, two, three, and four doses of IPV, to compute the number of susceptible and immune children by birth year. We validated our approach by comparing an intermediary output with zero-dose children (ZDC) estimated using data reported by WHO/UNICEF Estimates of National Immunization Coverage (WUENIC). Our results indicate high heterogeneity in susceptibility to PV2 across South Africa's 52 districts as of the end of 2022. In children under 5 years, PV2 susceptibility ranged from approximately 30 % in districts including Xhariep (31.9 %), Ekurhuleni (30.1 %), and Central Karoo (29.8 %), to less than 4 % in Sarah Baartman (1.9 %), Buffalo City (2.1 %), and eThekwini (3.2 %). Our susceptibility estimates were consistently higher than ZDC over the timeframe. We estimated that ZDC decreased nationally from 155,168 (152,737-158,523) in 2017 to 108,593 in 2021, and increased to 127,102 in 2022, a trend consistent with ZDC derived from data reported by WUENIC. While our approach provides a more comprehensive profile of PV2 susceptibility, our susceptibility and ZDC estimates generally agree in the ranking of districts according to risk.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bingham</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa. Electronic address: jeremyb@sun.ac.za.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulliam</LastName><ForeName>Juliet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mthombothi</LastName><ForeName>Zinhle</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sereo</LastName><ForeName>Tumelo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamupira</LastName><ForeName>Mercy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UNICEF, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botha</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Western Cape Department of Health, Expanded Programme on Immunisation, City of Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molema</LastName><ForeName>Koko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Department of Health, Expanded Programme on Immunisation, Pretoria, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maseti</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Department of Health, Expanded Programme on Immunisation, Pretoria, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schönfeldt</LastName><ForeName>Marione</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Department of Health, Expanded Programme on Immunisation, Pretoria, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabhena</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Right to Care, Centurion, Pretoria, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabdial-Sing</LastName><ForeName>Nishi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Gottberg</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Kerrigan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Schalkwyk</LastName><ForeName>Cari</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="Y">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073887" MajorTopicYN="Y">Vaccination Coverage</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="Y">Disease Eradication</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IPV</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword><Keyword MajorTopicYN="N">South Africa</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword><Keyword MajorTopicYN="N">Zero-dose children</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>6</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>21</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38969540</ArticleId><ArticleId IdType="pmc">PMC11413476</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.06.029</ArticleId><ArticleId IdType="pii">S0264-410X(24)00703-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Polio vaccines: WHO position paper – June 2022. World Health Organization; 2022. [Accessed 2024 February 16]. Available from: https://www.who.int/publications/i/item/WHO-WER9725-277-300.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Polio Eradication Strategy 2022–2026: Delivering on a promise. World Health Organization; 2021. [Accessed 2024 February 16]. Available from: https://polioeradication.org/wp-content/uploads/2022/06/Polio-Eradication-Strategy-2022-2026-Delivering-on-a-Promise.pdf.</Citation></Reference><Reference><Citation>Obregón R., Chitnis K., Morry C., Feek W., Bates J., Galway M., et al. Achieving polio eradication: a review of health communication evidence and lessons learned in India and Pakistan. Bull World Health Organ. 2009;87(8):624–630. doi: 10.2471/blt.08.060863.</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/blt.08.060863</ArticleId><ArticleId IdType="pmc">PMC2733260</ArticleId><ArticleId IdType="pubmed">19705014</ArticleId></ArticleIdList></Reference><Reference><Citation>Closser S., Cox K., Parris T.M., Landis R.M., Justice J., Gopinath R., et al. The impact of polio eradication on routine immunization and primary health care: a mixed-methods study. J Infect Dis. 2014 doi: 10.1093/infdis/jit232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit232</ArticleId><ArticleId IdType="pmc">PMC4197907</ArticleId><ArticleId IdType="pubmed">24690667</ArticleId></ArticleIdList></Reference><Reference><Citation>Deressa W., Kayembe P., Neel A.H., Mafuta E., Seme A., Alonge O. Lessons learned from the polio eradication initiative in the Democratic Republic of Congo and Ethiopia: analysis of implementation barriers and strategies. BMC Public Health. 2020;20(Suppl 4):1807. doi: 10.1186/s12889-020-09879-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09879-9</ArticleId><ArticleId IdType="pmc">PMC7747367</ArticleId><ArticleId IdType="pubmed">33339529</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyasulu J.C.Y., Maphoto R., Kamupira M.G.S., Msomi N. South Africa regains polio-free status: processes involved and lessons learnt. South Afr J Child Health. 2022;16(2):58. doi: 10.7196/SAJCH.2022.v16.i2.1822.</Citation><ArticleIdList><ArticleId IdType="doi">10.7196/SAJCH.2022.v16.i2.1822</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Global Wild Poliovirus 2018 ‐ 2024. World Health Organization; 2024. [Accessed 2024 February 16]. Available from: https://polioeradication.org/wp-content/uploads/2024/03/weekly-polio-analyses-WPV-20240312.pdf.</Citation></Reference><Reference><Citation>Department of Health, South Africa. Expanded programme on immunisation – EPI (SA) revised childhood immunisation schedule from December 2015. 2015. [Accessed 2024 February 16]. Available from: https://www.health.gov.za/wp-content/uploads/2020/11/epi-schedule.pdf.</Citation></Reference><Reference><Citation>National Institute for Communicable Diseases. Vaccine information for parents &amp; caregivers. Ideas Wise and Wonderful for National Institute for Communicable Diseases; 2016. [Accessed 2024 January 9]. Available from: https://www.nicd.ac.za/assets/files/NICD_Vaccine_Booklet_D132_FINAL.pdf.</Citation></Reference><Reference><Citation>Connor R.I., Brickley E.B., Wieland-Alter W.F., Ackerman M.E., Weiner J.A., Modlin J.F., et al. Mucosal immunity to poliovirus. Mucosal Immunol. 2022;15(1):1–9. doi: 10.1038/s41385-021-00428-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-021-00428-0</ArticleId><ArticleId IdType="pmc">PMC8732262</ArticleId><ArticleId IdType="pubmed">34239028</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Global Circulating Vaccine‐derived Poliovirus (cVDPV). World Health Organization; 2024. [Accessed 2024 February 16]. Available from: https://polioeradication.org/wp-content/uploads/2024/03/weekly-polio-analyses-cVDPV-20240312.pdf.</Citation></Reference><Reference><Citation>Voorman A., Lyons H.M. Measuring polio immunity to plan immunization activities. Vaccine. 2016;34(48):5946–5952. doi: 10.1016/j.vaccine.2016.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.017</ArticleId><ArticleId IdType="pmc">PMC5104692</ArticleId><ArticleId IdType="pubmed">27771181</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Immunization Agenda 2030: A global strategy to leave no one behind. World Health Organization; 2020. [Accessed 2023 February 3]. Available from: https://www.who.int/docs/default-source/immunization/strategy/ia2030/ia2030-document-en.pdf.</Citation></Reference><Reference><Citation>United Nations Children’s Fund (UNICEF). For every child, vaccination (Regional Brief: Eastern and Southern Africa: The state of the world’s children 2023). UNICEF; 2023. [Accessed 2023 October 23]. Available from: https://www.unicef.org/media/139221/file/SOWC23%20English%20%E2%80%93%20ESARO%20Brief.pdf.</Citation></Reference><Reference><Citation>Cooper L.V., Bandyopadhyay A.S., Gumede N., Mach O., Mkanda P., Ndoutabé M., et al. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Lancet Infect Dis. 2022;22(2):284–294. doi: 10.1016/S1473-3099(21)00453-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00453-9</ArticleId><ArticleId IdType="pmc">PMC8799632</ArticleId><ArticleId IdType="pubmed">34648733</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort A., Molodecky N.A., O’Reilly K.M., Wadood M.Z., Safdar R.M., Etsano A., et al. Population immunity against serotype-2 poliomyelitis leading up to the global withdrawal of the oral poliovirus vaccine: spatio-temporal modelling of surveillance data. PLoS Med. 2016;13(10):e1002140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049753</ArticleId><ArticleId IdType="pubmed">27701425</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson K.M., Badizadegan K. Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs) Expert Rev Vaccines. 2024;23(1):597–613. doi: 10.1080/14760584.2024.2361060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2024.2361060</ArticleId><ArticleId IdType="pubmed">38813792</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson K.M., Pallansch M.A., Tebbens R.J.D., Wassilak S.G., Cochi S.L. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013;33(4):647–663. doi: 10.1111/j.1539-6924.2012.01891.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2012.01891.x</ArticleId><ArticleId IdType="pmc">PMC7896539</ArticleId><ArticleId IdType="pubmed">22985171</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran RJ, Fagerholm ED, Cullen M, Daunizeau J, Richardson MP, Turkheimer F, et al. Estimating required ‘lockdown’ cycles before immunity to SARS-CoV-2: model-based analyses of susceptible population sizes, ‘S0’, in seven European countries including the UK and Ireland [version 1; peer review: 1 approved with reservations, 1 not approved]. Wellcome Open Res. 2020;5:85. 10.12688/wellcomeopenres.15886.1.</Citation></Reference><Reference><Citation>Stoner MCD, Angulo FJ, Rhea S, Brown LM, Atwell JE, Nguyen JL, et al. Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021. Open Forum Infect Dis. 2022;9(2):ofab647. 10.1093/ofid/ofab647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8774091</ArticleId><ArticleId IdType="pubmed">35071687</ArticleId></ArticleIdList></Reference><Reference><Citation>Uwamino Y., Nagashima K., Yoshifuji A., Suga S., Nagao M., Fujisawa T., et al. Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination. NPJ Vaccines. 2023 doi: 10.1038/s41541-023-00626-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00626-w</ArticleId><ArticleId IdType="pmc">PMC9988198</ArticleId><ArticleId IdType="pubmed">36878929</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A., Lyons H., Bennette C., Kovacs S., Makam J.K., Vertefeuille J.F., et al. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2023;41(Supplement 1):A85–A92. doi: 10.1016/j.vaccine.2022.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.013</ArticleId><ArticleId IdType="pmc">PMC10973941</ArticleId><ArticleId IdType="pubmed">35339308</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. South Africa: WHO and UNICEF estimates of immunization coverage: 2022 revision. World Health Organization; 2022. [Accessed February 13]. Available from: https://cdn.who.int/media/docs/default-source/country-profiles/immunization/2023-country-profiles/immunization_zaf_2023.pdf?sfvrsn=3359aa13_4&amp;download=true.</Citation></Reference><Reference><Citation>Statistics South Africa (Stats SA). Mid-year population estimates: 2022. (Statistical Release P0302). Stats SA; 2023. [Accessed 2024 February 16]. Available from: https://www.statssa.gov.za/publications/P0302/P03022022.pdf.</Citation></Reference><Reference><Citation>Johnson L.F., Meyer-Rath G., Dorrington R.E., Puren A., Seathlodi T., Zuma K., et al. The effect of HIV Programs in South Africa on National HIV Incidence Trends, 2000–2019. JAIDS J Acquir Immune Defic Syndr. 2022;90(2):115–123. doi: 10.1097/QAI.0000000000002927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000002927</ArticleId><ArticleId IdType="pubmed">35125471</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly N.C. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J Infect Dis. 2014 doi: 10.1093/infdis/jit601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit601</ArticleId><ArticleId IdType="pmc">PMC4197908</ArticleId><ArticleId IdType="pubmed">24634499</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L., et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201(9):1344–1352. doi: 10.1086/651611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/651611</ArticleId><ArticleId IdType="pubmed">20350164</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis. 1997;175(Supplement 1):S215–S227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed A.J., AlAwaidy S., Bawikar S., Kurup P.J., Elamir E., Shaban M.M.A., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362(25):2351–2359. doi: 10.1056/NEJMoa0909383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0909383</ArticleId><ArticleId IdType="pubmed">20573923</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain P.K., Dutta A.K., Nangia S., Khare S., Saili A. Seroconversion following killed polio vaccine in neonates. Indian J Pediatr. 1997;64(4):511–515. doi: 10.1007/BF02737758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02737758</ArticleId><ArticleId IdType="pubmed">10771880</ArticleId></ArticleIdList></Reference><Reference><Citation>Larocca A.M.V., Bianchi F.P., Bozzi A., Tafuri S., Stefanizzi P., Germinario C.A. Long-term immunogenicity of inactivated and oral polio vaccines: an Italian retrospective cohort study. Vaccines. 2022;10(8):1329. doi: 10.3390/vaccines10081329.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081329</ArticleId><ArticleId IdType="pmc">PMC9413249</ArticleId><ArticleId IdType="pubmed">36016217</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan R., Jadhav M., John T.J. Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ. 1983;61(4):689–692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2536153</ArticleId><ArticleId IdType="pubmed">6605215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobo F.T., Asante A., Woldie M., Dawson A., Hayen A. Child vaccination in sub-Saharan Africa: increasing coverage addresses inequalities. Vaccine. 2022;40(1):141–150. doi: 10.1016/j.vaccine.2021.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.11.005</ArticleId><ArticleId IdType="pubmed">34794824</ArticleId></ArticleIdList></Reference><Reference><Citation>Cata-Preta B.O., Santos T.M., Mengistu T., Hogan D.R., Barros A.J.D., Victora C.G. Zero-dose children and the immunisation cascade: understanding immunisation pathways in low and middle-income countries. Vaccine. 2021;39(32):4564–4570. doi: 10.1016/j.vaccine.2021.02.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.02.072</ArticleId><ArticleId IdType="pmc">PMC8314014</ArticleId><ArticleId IdType="pubmed">33744046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>